Amgen Inc. LS-Bonds 2011(26)
- BID
100.394
- ASK
100.452
- 100,000 Nom.100,000 Nom.
- 07/27, 19:04:41 PM
Type of financial instrument
Corporate Bond
Sub-Type
Health Care
Yield
4.33
Yield spread Bundesanleihe
1.5102
Tradable for private investors
Yes
Minimum amount tradeable unit
100,000.00
Maturity
07/12/2026
Interest Rate
5.50 %
Currency
British Pound Sterling
Facts & figures
Price data
| TRADE PLATFORM | ||
| LAST PRICE / YIELD | 100.394 G / 4.33 | 0 Units |
| PRICE DETERMINATION TIME | 07/27/2026 / 07:04:41 PM | |
| DAILY VOLUME (NOMINAL) | 0 | |
| YIELD SPREAD | 1.5102 | |
| FIXINGPRICE | - | |
| DAILY HIGH / LOW | 100.42 | 100.39 |
| PREV. DAY'S PRICE | 100.417 | (07/24) |
| CHANGE DAY BEFORE | -0.02 | -0.02 % |
| 52 WEEK HIGH / LOW | 101.4 (08/04) | 100.22 (03/23) |
Master Data
| WKN | A1GX0L |
| ISIN | XS0710091140 |
| SYMBOL | AMGA |
| EXCHANGE SEGMENT | Freiverkehr |
| TYPE OF FINANCIAL INSTRUMENT | Corporate Bond |
| SUB-TYPE | Health Care |
| ISSUER | Amgen Inc. |
| S&P RATING | Please log in to view this field |
| (TRADING) SEGMENT / TICKS | -/ - |
| TRADING HOURS | 07:30:00 AM - 10:00:00 PM |
| INTEREST RATE | 5.50 % |
| INTEREST RUN FROM | 05/12/2011 |
| NEXT INTEREST PAYMENT | 07/12/2026 |
| UNIT INTEREST FROM NOMINAL AMMOUNT | 3.526 % |
| TRADING CURRENCY / NOTATION | British Pound Sterling/ Percent |
| NOMINAL CURRENCY | British Pound Sterling |
| SETTLEMENT CURRENCY | Euro |
| QUOTATION | Continuous trading |
| ISSUING VOLUME | 475.00 Mil. |
| MINIMUM AMOUNT TRADEABLE UNIT | 100,000.00 |
| SMALLEST TRADEABLE UNIT | 1,000.00 |
| MATURITY | 07/12/2026 |
| MARKET MAKER | - |
| STEP UP/ DOWN WHEN RATING CHANGES | No |
| STEP UP FIXED AT ISSUE | No |
| STEP DOWN FIXED AT ISSUE | No |
| BOND CALLABLE BY THE ISSUER | No |
| BOND IS SUBORDINATED | No |
Description
Local currency bond: GBP.
Tradability Information
Please log in to see the tradability information for this stock.Not registered yet? Create your free account here.
Company profile
Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.